Warning: fopen(/home/virtual/epih/journal/upload/ip_log/ip_log_2024-10.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 95 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 96 Predictors of tuberculosis and human immunodeficiency virus co-infection: a case-control study
Skip Navigation
Skip to contents

Epidemiol Health : Epidemiology and Health

OPEN ACCESS
SEARCH
Search
Advanced Search
mobile menu button

Articles

Page Path
HOME > Epidemiol Health > Volume 36; 2014 > Article
Original Article
 Predictors of tuberculosis and human immunodeficiency virus co-infection: a case-control study
Leila Molaeipoor1, Jalal Poorolajal2, Minoo Mohraz3, Nader Esmailnasab4
Epidemiol Health 2014;36:e2014024.
DOI: https://doi.org/10.4178/epih/e2014024
Published online: October 30, 2014

1Department of Epidemiology and Biostatistics, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran

2Research Center for Health Sciences and Department of Epidemiology and Biostatistics, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran

3Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Science, Tehran, Iran

4Kurdistan Research Center for Social Determinants of Health, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran

Correspondence: Jalal Poorolajal Research Center for Health Sciences and Department of Epidemiology and Biostatistics, School of Public Health, Hamadan University of Medical Sciences, Hamadan 65157838695, Iran Tel: +98-81-38380090, Fax: +98-81-38380509 E-mail: poorolajal@umsha.ac.ir, poorolajal@yahoo.com
• Received: September 12, 2014   • Accepted: October 30, 2014

©2014, Korean Society of Epidemiology

This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next
  • 20,510 Views
  • 184 Download
  • 25 Web of Science
  • 17 Crossref
Full Article

Download PDF Download PDF

  • OBJECTIVES:
    The human immunodeficiency virus (HIV) and Mycobacterium tuberculosis co-infection is a major global challenge. It is not clear why some HIV-positive people are co-infected with tuberculosis (TB) while others are not. This study addressed that question.
  • METHODS:
    This case-control study was conducted in Tehran, Iran in June 2004, enrolling 2,388 HIV-positive people. Cases were selected from those who were co-infected with TB and controls from those without TB. Multiple logistic regression analysis was performed to assess the association between M. tuberculosis/HIV co-infection and several predictors. Odds ratios (ORs) and their 95% confidence intervals (CIs) were calculated.
  • RESULTS:
    In this study, 241 cases were compared with 2,147 controls. Sex, age, marital status, educational level, imprisonment, smoking, narcotic use, route of HIV transmission, previous TB infection, isoniazid preventive therapy (IPT), antiretroviral therapy (ART), and low CD4 count (<350 cells/mm3) were independently associated with M. tuberculosis/HIV co-infection (p<0.001). However, after adjusting for all other variables in the model, only the association between M. tuberculosis/HIV co-infection and the following predictors remained statistically significant: imprisonment (odds ratio [OR], 3.82; 95% confidence interval [CI], 2.11-6.90), previous TB infection (OR, 5.54; 95% CI, 1.99-15.39), IPT (OR, 0.13; 95% CI, 0.06-0.31), ART (OR, 1.81; 95% CI, 1.26-2.61), and CD4 count <350 cells/mm3 (OR, 2.34; 95% CI, 1.36-4.02).
  • CONCLUSIONS:
    Several predictors are associated with M. tuberculosis/HIV co-infection, but only a few indicators were significantly associated with M. tuberculosis/HIV co-infection. It is estimated that a number of predictors of M. tuberculosis/HIV co-infection remain unknown and require further investigation.
  • Keywords: Human immunodeficiency virus, Acquired immunodeficiency syndrome, Tuberculosis, Risk factors, Case-control studies, Iran
To halt and reverse the tuberculosis (TB) epidemic by 2015 is the sixth Millennium Development Goals [1]. The human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) and Mycobacterium tuberculosis co-infection is one of the major global challenges in the control of TB [2]. The risk of developing TB is 20-37 times greater in HIV-positive people than HIV-negative people [3]. TB is the leading preventable cause of death among HIV-infected people [2] and is responsible for more than 25% of deaths in people living with HIV [3]. TB increases the risk of HIV-related mortality by 4.5fold [4]. In 2012, there were an estimated 8.6 million new cases of TB and 1.3 million died from TB. Over 95% of TB cases and deaths occur in low- and middle-income countries [5].
There are several conditions associated with increased risk of M. tuberculosis/HIV co-infection. Men living with HIV are more likely to be infected with TB than women [6-8]. The TB prevalence shows a bimodal distribution at the extremes of age [9]. The active TB is more common in immunosuppressed people [5]. People who live in close contact with people who have active TB are more likely to be infected with TB [10]. In HIV-positive people, the probability of TB increases as the CD4 cell count decreases [7,8,10,11]. Tobacco use is substantially associated with increased risk of disease and mortality caused by TB [5]. Anemia and iron deficiency disorders are associated with an increased risk of TB [12,13]. Low body mass index can increase the probability of the TB infection [14,15].
Several studies have been conducted worldwide to assess the predictors of M. tuberculosis/HIV co-infection [9,11-15]. However, the prognostic factors behind the breakdown in immune defenses associated with TB infection in people living with HIV are not fully understood. It is unclear why some HIV-positive people are co-infected with TB while others are not. Until reliable information on predictors of TB is collected, it will remain difficult to design effective preventive intervention strategies to control TB in HIV-infected people. This case-control study was conducted in a large population in Iran to determine the main prognostic factors associated with HIV and M. tuberculosis co-infection.
This case-control study was conducted in the megacity of Tehran, Iran in June 2004. The Research Council of Hamadan University of Medical Sciences approved the study. The study population was HIV-positive people with or without TB who had a medical record in one of two Behavioral Diseases Counseling Centers, the Imam Khomeini and Zamzam Centers. These centers provide several health services, such as education, counseling, self-care, prevention, treatment, and harm reduction, to people who are at high risk of HIV and sexually transmitted diseases [16].
The cases were selected from HIV-positive people co-infected with TB aged equal to or greater than 18 years irrespective of sex and date of diagnosis, whether or not they had developed AIDS. The additional data on TB infection were extracted from the Centers for Disease Control and Prevention. The controls were selected from HIV-positive people without TB. The controls were selected from a control group from the same database from which the cases were selected in order to make the study base of the two groups the same.
The data collection was done using a checklist of items which was developed according to the information documented in the medical records including demographic information (age, sex, marital status, and educational level), behavioral information (narcotic/alcohol abuse, smoking, and imprisonment), and additional information such as co-infection with hepatitis C virus (HCV), history of previous TB infection, anti-TB prophylaxis, antiretroviral therapy (ART), and CD4 cell count per cubic millimeter. The people with school education (less than or equal to 12 years education) was considered as less educated and those with university education (more than 12 years education) were considered as highly educated.
An HIV-positive subject was defined as an individual with HIV infection irrespective of clinical stage confirmed by laboratory criteria according to country definitions and requirements [17]. In the Islamic Republic of Iran, a case of HIV is defined as a positive result for HIV antibody by two sequential enzyme-linked immunosorbent assay tests confirmed by a western blot test [18]. A case of AIDS was defined as a presumptive or definitive diagnosis of stage 3 or 4 conditions and/or a CD4 count less than 350 cells/mm3 of blood in an HIV-infected subject [17].
Active TB was defined as a disease that is caused by M. tuberculosis in any part of the body and that is in an active state. In the Islamic Republic of Iran, a patient with two positive sputum smears or one positive sputum smear plus a positive sputum culture or a chest X-ray demonstrating pulmonary TB is considered to have sputum-positive pulmonary TB. A patient with two negative sputum smears but with a positive sputum culture or with signs and symptoms of pulmonary TB not responding to a two-week broad-spectrum antibiotic treatment is considered to have sputum-negative pulmonary TB. Extra-pulmonary TB is diagnosed with bacteriological evidence (positive culture) and pathological findings (caseous necrosis) [19].
Adults and adolescents living with HIV who are unlikely to have active TB, based on a clinical algorithm screening, should receive isoniazid preventive therapy (IPT) for at least 6 months (10 mg/kg/d) as part of a comprehensive package of HIV prevention and care services [2]. In the Islamic Republic of Iran, after excluding active TB, HIV-positive patients with the following criteria will receive IPT: (a) TB skin test (purified protein derivative skin test) equal to or greater than 5 mm; (b) close contact with an infectious TB case; and (c) chest X-ray findings suggestive of fibrotic lesions consistent with TB [16].
Logistic regression analysis was performed to determine the factors predictive of M. tuberculosis/HIV co-infection. To control the effect of potential confounding factors, a backward stepwise adjusted analysis was performed to fit the data well and to exclude unnecessary variables from the model. For this purpose, we started with the full model and then excluded variables one at a time, while using the likelihood ratio test to check whether the reduced model or the full model fitted the data significantly well. Crude and adjusted odds ratios (ORs) were reported to address the effect of predictors associated with M. tuberculosis/HIV co-infection. All statistical analyses were performed at a significance level of 0.05 using Stata version 11 (StataCorp, College Station, TX, USA).
We identified 2,519 patients; 25 were ineligible, 21 had medical records in both centers, and 85 were aged below 18 years. The analysis was based on data from the remaining 2,388 people (241 cases and 2,147 controls), of which 1,889 were men and 499 were women. The mean standard deviation age of the patients was 34.99 (8.84) years and ranged from 18 to 74 years.
Results from the bivariate logistic regression analysis of predictors associated with M. tuberculosis/HIV co-infection are given in Table 1. There was a highly significant association between male sex and M. tuberculosis/HIV co-infection. The risk of TB increased significantly with age. Compared to married people, the single, divorced, or widowed people were at higher risk of infection with TB. The risk of co-infection with TB was higher in highly educated individuals than in those with less education. Imprisonment, smoking, and narcotic use were associated with increased the risk of M. tuberculosis/HIV co-infection significantly. Compared to the sexual route of infection, intravenous drug use and multiple routes of HIV transmission were associated with an increased risk of TB. Heterosexuality increased the risk of TB more than other modes of sexual transmission. History of previous TB infection was the strongest risk factor for M. tuberculosis/HIV co-infection. The HIV-positive individuals who were co-infected with HCV had a greater risk of co-infection with TB as well. Preventive treatment with isoniazid decreased the risk of TB to less than one-fifth in HIV-positive people. The CD4 cell count less than 350 cells/mm3 was associated with an increased risk of TB so that the lower the CD4 cell count, the higher the risk of M. tuberculosis/HIV co-infection.
Results from the multivariate logistic regression analysis of predictors associated with M. tuberculosis/HIV co-infection are given in Table 2. The pseudo R2 statistic, which assesses the predictive strength of the logistic regression, was 0.1444. In order to control the effect of potential confounding and to fit the data well, a backward stepwise adjusted analysis was performed, and the unnecessary variables were excluded from the model. Eight variables remained in the final model, of which only five predictive factors were strongly associated with M. tuberculosis/HIV co-infection including imprisonment, previous TB infection, IPT, ART, and reduced CD4 cell count.
Reducing the TB pandemic by 2015 is the sixth Millennium Development Goals [1]. To better understand the risk factors of TB infection in people who live with HIV, the association between several predictors and M. tuberculosis/HIV co-infection was investigated. We found that sex, age, marital status, educational level, smoking, narcotic use, and route of HIV transmission were independently associated with increased risk of TB infection in people living with HIV. However, the multivariate analysis revealed no association between these variables and M. tuberculosis/HIV co-infection. On the other hand, there was a strong association between M. tuberculosis/HIV co-infection and imprisonment, previous TB infection, IPT, ART, and CD4 cell count less than 350 cells/mm3.
Current studies have reported that the risk of M. tuberculosis/HIV co-infection increases with male sex [6-8], age [9], and tobacco use [5], as was the case in our study. However, multivariate analysis revealed that the associations between M. tuberculosis/HIV co-infection and male sex, age, and smoking were confounded by other variables. According to our results, age and smoking do not increase the risk of TB infection in HIV-positive people. On the other hand, current studies have shown that the risk M. tuberculosis/HIV co-infection is higher among people who are immunosuppressed [5] or live in close contact with people who have active TB [10] or have a CD4 cell count below 200 cells/mm3 [10,11]. Our results were consistent with these findings. Multivariate analysis indicated that previous TB infection and CD4 cell count less than 350 cells/mm3 substantially increased the risk of TB in people living with HIV.
We noted that previous imprisonment was related to an increased risk of M. tuberculosis/HIV co-infection. Inmates are at a high risk of TB infections because they generally receive minimal preventive care and access to treatment facilities [20]. In addition, inadequate health services may increase the risk of unmanageable HIV and TB epidemics in prisons [21,22].
According to our results, IPT was the most efficient intervention to prevent TB in people who live with HIV and could reduce the risk of TB by 87%. This finding is consistent with current evidence. Current studies have shown that IPT can significantly reduce the risk of TB in people living with HIV in various settings, especially in TB-endemic settings [23,24].
We reported an inverse association between the prevalence of M. tuberculosis/HIV co-infection and CD4 cell count, such that the risk of co-infection increased as the CD4 cell count decreased. This finding is consistent with the current evidence [10, 11]. On the other hand, we found that HIV-positive people who received ART were at a higher risk of M. tuberculosis/HIV co-infection. The reason is straightforward. ART was initiated for the HIV patients when they developed stage 3 or 4 characteristics or their CD4 cell count decreased to below 350 cells/μL. Both of these conditions can increase the risk of M. tuberculosis/HIV co-infection [7,8,10,11].
According to our results, high risk behaviors were more common in cases than in controls. These included imprisonment (80.08% vs. 60.92%), narcotic use (66.80% vs. 51.47%), alcohol use (6.36% vs. 4.15%), smoking (69.05% vs. 55.13%), and previous history of TB infection (4.15% vs. 0.75%). These high risk behaviors might predispose HIV patients to TB infection.
This study had a few limitations. First, this study was performed on data recorded at the Behavioral Diseases Counseling Centers. The quality and accuracy of the associations reported in this study primarily depend on the quality of the recorded data, but we were unable to verify the accuracy of the data. This raises the possibility of information bias. Second, despite several predictors assessed in this study, the value of the pseudo R2 statistic that indicates the predictive strength of the logistic regression was low. This demonstrates that there are still many unknown factors that affect the incidence of TB in people with HIV. Despite its limitations, this study was conducted on a large dataset in the megacity of Tehran, which comprises about 20% of the Iranian population. Therefore, the results of this study may be generalized to a majority of the Iranian HIV-infected population. Furthermore, the effects of several predictive factors on M. tuberculosis/HIV co-infection were evident in a middle income country. Such information may be useful for establishing preventive measures.
According to the results of this study, despite the fact that several modifiable and non-modifiable predictors were independently associated with M. tuberculosis/HIV co-infection, it was evident that only a few indicators such as imprisonment, previous TB infection, IPT, ART, and low CD4 cell count (<350 cells/ mm3) had a significant effect on M. tuberculosis/HIV co-infection. In addition, there are still several unknown predictors that affect the association between HIV and TB and require further investigation.
The paper was part of an MSc thesis in Epidemiology. We would like to express our appreciation to the Vice Chancellor of Education for technical support and the Vice Chancellor of Research and Technology of Hamadan University of Medical Sciences for financial support of this work. We also thank the staff members and managers of the Imam Khomeini and Zamzam Behavioral Diseases Counseling Centers for their collaboration with this study.

The author has no conflicts of interest to declare for this study.

Table 1.
Results from the bivariate logistic regression analysis of binary and continuous predictors of M. tuberculosis/HIV co-infection using unadjusted odds ratios (ORs)
Variables TB cases (HIV+/TB+)1 (n=241) Non-TB cases (HIV+/TB-)2 (n=2,147) Unadjusted OR (95% CI) p-value
Gender
 Female 19 (7.88) 480 (22.36) 1.00
 Male 222 (92.12) 1,667 (77.64) 3.36 (2.08-5.43) 0.001
Age (yr)
 18-29 47 (19.50) 636 (29.75) 1.00
 30-39 111 (46.06) 956 (44.71) 1.57 (1.10-2.24) 0.01
 ≥40 83 (34.44) 546 (25.54) 2.06 (1.41-3.00) 0.001
Marital status
 Married 76 (32.76) 832 (40.88) 1.00
 Single 101 (43.53) 782 (38.43) 1.41 (1.03-1.93) 0.03
 Divorced 44 (18.97) 315 (15.48) 1.53 (1.03-2.27) 0.03
 Widowed 11 (4.74) 106 (5.21) 1.14 (0.58-2.21) 0.71
Educational level
 High (>12 yr) 8 (3.72) 146 (7.97) 1.00
 Low (≤12 yr) 207 (96.28) 1,685 (92.03) 2.24 (1.08-4.63) 0.03
Imprisonment
 No 48 (19.92) 839 (39.08) 1.00
 Yes 193 (80.08) 1,308 (60.92) 2.58 (1.86-3.58) 0.001
Smoker
 No 65 (30.95) 853 (44.87) 1.00
 Yes 145 (69.05) 1,048 (55.13) 1.82 (1.34-2.47) 0.001
Narcotic use
 No 80 (33.20) 1,042 (48.53) 1.00
 Yes 161 (66.80) 1,105 (51.47) 1.90 (1.43-2.51) 0.001
Alcohol use
 No 221 (93.64) 2,031 (95.85) 1.00
 Yes 15 (6.36) 88 (4.15) 1.57 (0.89-2.76) 0.12
Route of HIV transmission
 Sexual 21 (8.71) 494 (23.01) 1.00
 Intravenous drug users 116 (48.13) 751 (34.98) 3.63 (2.25-3.86) 0.001
 Transfusion 5 (2.07) 66 (3.07) 1.78 (0.65-4.89) 0.26
 Tattoos 2 (0.83) 26 (1.21) 1.81 (0.40-8.13) 0.44
 Surgery or dentistry 2 (0.83) 20 (0.93) 2.35 (0.52-10.73) 0.27
 Multiple exposure 87 (36.10) 680 (31.67) 3.01 (1.84-4.91) 0.001
 Unknown 8 (3.32) 110 (5.12) 1.71 (0.74-3.96) 0.21
Sexual route of transmission
 Spouse 15 (16.85) 358 (34.52) 1.00
 Heterosexual 68 (76.40) 597 (57.57) 2.72 (1.53-4.83) 0.001
 Homosexual 1 (1.12) 26 (2.51) 0.92 (0.12-7.22) 0.93
 Bisexual 5 ( 5.62) 56 (5.40) 2.13 (0.75-6.09) 0.16
Previous TB infection
 No 231 (95.85) 2,131 (99.25) 1.00
 Yes 10 (4.15) 16 (0.75) 5.77 (2.59-12.85) 0.001
Hepatitis C virus
 No 111 (46.06) 1,253 (58.36) 1.00
 Yes 130 (53.94) 894 (41.64) 1.64 (1.26-2.15) 0.001
Isoniazid preventive therapy
 No 234 (97.10) 1,811 (84.35) 1.00
 Yes 7 (2.90) 336 (15.65) 0.16 (0.08-0.35) 0.001
Antiretroviral therapy
 No 1,356 (63.16) 136 (56.43) 1.00
 Yes 791 (36.84) 105 (43.57) 1.32 (1.01-1.73) 0.04
CD4 cell count (cells/mm3)
 ≥350 33 (16.92) 656 (38.54) 1.00
 201-249 34 (17.44) 380 (22.33) 1.78 (2.66-6.62) 0.02
 50-200 74 (37.95) 410 (24.09) 3.59 (2.34-5.51) 0.001
 <50 54 (27.69) 256 (15.04) 4.19 (2.66-6.61) 0.001
 Trend test for strata of CD4 count 241 (100.00) 2,147 (100.00) 1.64 (1.43-1.88) 0.001

HIV, human immunodeficiency virus;TB, tuberculosis; CI, confidence interval.

1 HIV+/TB+, human immunodeficiency virus positive patients with Mycobacterium tuberculosis co-infection;

2 HIV+/TB-, human immunodeficiency virus positive patients without Mycobacterium tuberculosis co-infection.

Table 2.
Results from the multivariate logistic regression analysis of binary and continuous predictors of M. tuberculosis/HIV co-infection using odds ratios (ORs) adjusted for all other variables in the model (pseudo R2=0.144)
Variables TB cases (HIV+/TB+)1 (n=241) Non-TB cases (HIV+/TB-)2 (n=2,147) Adjusted OR (95% CI) p-value
Marital status
 Married 76 (32.76) 832 (40.88) 1.00
 Single 101 (43.53) 782 (38.43) 0.95 (0.63-1.45) 0.82
 Divorced 44 (18.97) 315 (15.48) 1.09 (0.66-1.81) 0.74
 Widow 11 (4.74) 106 (5.21) 1.57 (0.72-3.39) 0.25
Educational level
 High (>12 yr) 8 (3.72) 146 (7.97) 1.00
 Low (≤12 yr) 207 (96.28) 1,685 (92.03) 0.93 (0.43-2.05) 0.86
Imprisonment
 No 48 (19.92) 839 (39.08) 1.00
 Yes 193 (80.08) 1,308 (60.92) 3.82 (2.11-6.90) 0.001
Smoker
 No 65 (30.95) 853 (44.87) 1.00
 Yes 145 (69.05) 1,048 (55.13) 1.27 (0.77- 2.10) 0.36
Previous TB infection
 No 231 (95.85) 2,131 (99.25) 1.00
 Yes 10 (4.15) 16 (0.75) 5.54 (1.99- 15.39) 0.001
Isoniazid preventive therapy
 No 234 (97.10) 1,811 (84.35) 1.00
 Yes 7 (2.90) 336 (15.65) 0.13 (0.06-0.31) 0.001
Antiretroviral therapy
 No 1,356 (63.16) 136 (56.43) 1.00
 Yes 791 (36.84) 105 (43.57) 1.81 (1.26-2.61) 0.001
CD4 cell count (cells/mm3)
 ≥350 33 (16.92) 656 (38.54) 1.00
 201-249 34 (17.44) 380 (22.33) 2.15 (1.25-3.72) 0.006
 50-200 74 (37.95) 410 (24.09) 3.31 (2.01-5.45) 0.001
 <50 54 (27.69) 256 (15.04) 4.57 (2.69-7.76) 0.001
 Trend test for strata of CD4 count 241 (100.00) 2,147 (100.00) 1.70 (1.45-1.99) 0.001

HIV, human immunodeficiency virus; TB, tuberculosis; CI, confidence interval.

1 HIV+/TB+, human immunodeficiency virus positive patients with Mycobacterium tuberculosis co-infection;

2 HIV+/TB-, human immunodeficiency virus positive patients without Mycobacterium tuberculosis co-infection.

  • 1. World Health Organization. Global tuberculosis report; 2012 [cited 2014 Nov 13]. Available from: http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf .
  • 2. World Health Organization. WHO policy on collaborative TB/HIV activities: guidelines for national programmes and other stakeholders; 2012 [cited 2014 Nov 13]. Available from: http://apps.who.int/iris/bitstream/10665/44789/1/9789241503006_eng.pdf?ua=1&ua=1.
  • 3. World Health Organization. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resourceconstrained settings; 2011 [cited 2014 Nov 13]. Available from: http://whqlibdoc.who.int/publications/2011/9789241500 708_eng.pdf.
  • 4. Mirzaei M, Poorolajal J, Khazaei S, Saatchi M. Survival rate of AIDS disease and mortality in HIV-infected patients in Hamadan, Iran: a registry-based retrospective cohort study (1997-2011). Int J STD AIDS 2013;24:859-866.ArticlePubMed
  • 5. World Health Organization. Tuberculosis (TB). [cited 2014 Nov 13]. Available from: http://www.who.int/topics/tuberculosis/en/.
  • 6. Getahun H, Gunneberg C, Granich R, Nunn P. HIV infection-associated tuberculosis: the epidemiology and the response. Clin Infect Dis 2010;50 Suppl 3:S201-S207.Article
  • 7. Fenner L, Forster M, Boulle A, Phiri S, Braitstein P, Lewden C, et al. Tuberculosis in HIV programmes in lower-income countries: practices and risk factors. Int J Tuberc Lung Dis 2011;15:620-627.ArticlePubMedPMC
  • 8. Hermans SM, Kiragga AN, Schaefer P, Kambugu A, Hoepelman AI, Manabe YC. Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan Africa. PLoS One 2010;5:e10527.ArticlePubMedPMC
  • 9. Awoyemi OB, Ige OM, Onadeko BO. Prevalence of active pulmonary tuberculosis in human immunodeficiency virus seropositive adult patients in University College Hospital, Ibadan, Nigeria. Afr J Med Med Sci 2002;31:329-332.PubMed
  • 10. International Association of Providers of Aids Care. Tuberculosis (TB); 2014 [cited 2014 Oct 10]. Available from: http://www.aidsinfonet.org/fact_sheets/view/518.Article
  • 11. Hwang JH, Choe PG, Kim NH, Bang JH, Song KH, Park WB, et al. Incidence and risk factors of tuberculosis in patients with human immunodeficiency virus infection. J Korean Med Sci 2013;28:374-377.ArticlePubMedPMC
  • 12. McDermid JM, Hennig BJ, van der Sande M, Hill AV, Whittle HC, Jaye A, et al. Host iron redistribution as a risk factor for incident tuberculosis in HIV infection: an 11-year retrospective cohort study. BMC Infect Dis 2013;13:48.ArticlePubMedPMC
  • 13. Saathoff E, Villamor E, Mugusi F, Bosch RJ, Urassa W, Fawzi WW. Anemia in adults with tuberculosis is associated with HIV and anthropometric status in Dar es Salaam, Tanzania. Int J Tuberc Lung Dis 2011;15:925-932.ArticlePubMedPMC
  • 14. Choun K, Thai S, Pe R, Lorent N, Lynen L, van Griensven J. Incidence and risk factors for tuberculosis in HIV-infected patients while on antiretroviral treatment in Cambodia. Trans R Soc Trop Med Hyg 2013;107:235-242.ArticlePubMed
  • 15. Maro I, Lahey T, MacKenzie T, Mtei L, Bakari M, Matee M, et al. Low BMI and falling BMI predict HIV-associated tuberculosis: a prospective study in Tanzania. Int J Tuberc Lung Dis 2010;14:1447-1453.PubMedPMC
  • 16. Radfar S, Taheri K, Namdari Tabar H. Executive instruction services at the Counseling Center Behavioral Disorders. Tehran: Ministry of Health and Medical Education; 2010. (Persian).
  • 17. World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children; 2006 [cited 2014 Oct 10]. Available from: http://www.who.int/hiv/pub/guidelines/hivstaging/en/ .
  • 18. Radfar S, Taheri K, Namdari Tabar H. Practical guidelines on how to provide consulting services in behavioral disorders centers. Tehran: Ministry of Health and Medical Education; 2009. (Persian).
  • 19. Ministry of Health and Medical Education (MOHME). National guideline for HIV/AIDS control and treatment. Tehran: MOHME; 2011. (Persian).
  • 20. Zumla A, Atun R, Maeurer M, Kim PS, Jean-Philippe P, Hafner R, et al. Eliminating tuberculosis and tuberculosis-HIV co-disease in the 21st century: key perspectives, controversies, unresolved issues, and needs. J Infect Dis 2012;205 Suppl 2:S141-S146.ArticlePubMedPMC
  • 21. Reid SE, Topp SM, Turnbull ER, Hatwiinda S, Harris JB, Maggard KR, et al. Tuberculosis and HIV control in sub-Saharan African prisons: “thinking outside the prison cell”. J Infect Dis 2012;205 Suppl 2:S265-S273.Article
  • 22. Henostroza G, Topp SM, Hatwiinda S, Maggard KR, Phiri W, Harris JB, et al. The high burden of tuberculosis (TB) and human immunodeficiency virus (HIV) in a large Zambian prison: a public health alert. PLoS One 2013;8:e67338.ArticlePubMedPMC
  • 23. Khawcharoenporn T, Apisarnthanarak A, Manosuthi W, Sungkanuparph S, Mundy LM. Isoniazid preventive therapy and 4-year incidence of pulmonary tuberculosis among HIV-infected Thai patients. Int J Tuberc Lung Dis 2012;16:336-341.ArticlePubMed
  • 24. Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, Shang N, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet 2011;377:1588-1598.ArticlePubMed

Figure & Data

References

    Citations

    Citations to this article as recorded by  
    • Joint Modeling of Longitudinal Outcome and Competing Risks: Application to HIV/AIDS Data
      Khadijeh Najafi Ghobadi, Hossein Mahjub, Jalal Poorolajal, Ebrahim Shakiba, Kaivan Khassi, Ghodratollah Roshanaei
      Journal of Research in Health Sciences.2023; 23(1): e00571.     CrossRef
    • Clinico-epidemiological Determinants of Tuberculosis Co-infection among Adults Attending an Antiretroviral Centre at a Tertiary Care Hospital in Madhya Pradesh
      Preeti Gupta, Akanksha Tomar, Manoj Bansal, Rajesh Kumar Gupta
      Journal of Medical Evidence.2023; 4(3): 220.     CrossRef
    • The Occurrence of Tuberculosis Infection among Newly HIV Diagnosed Patient in Indonesia
      Rengga Rusfa Gumilang, Dwi Wahyu Indriati, Diyantoro Diyantoro, Aliyah Siti Sundari
      Open Access Macedonian Journal of Medical Sciences.2022; 10(A): 893.     CrossRef
    • Effect of Isoniazid Prophylaxis Therapy on the Prevention of Tuberculosis Incidence and Associated Factors Among HIV Infected Individuals in Northwest Ethiopia: Retrospective Cohort Study
      Mulat Addis Beshaw, Shitaye Alemu Balcha, Ayenew Molla Lakew
      HIV/AIDS - Research and Palliative Care.2021; Volume 13: 617.     CrossRef
    • EFFICIENCY OF TREATMENT OF THE FIRST DETECTED TUBERCULOSIS DEPENDING ON THE HIV STATUS IN THE TUBERCULOSIS INSTITUTION OF THE FEDERAL PENITENTIARY SERVICE
      V. S. Borovitsky
      HIV Infection and Immunosuppressive Disorders.2020; 12(1): 83.     CrossRef
    • Determinants of Active Tuberculosis Occurrences after ART Initiation among Adult HIV-Positive Clients in West Showa Zone Public Hospitals, Ethiopia: A Case-Control Study
      Gerbaba Guta Nugus, Mergitu Eliyas Irena
      Advances in Public Health.2020; 2020: 1.     CrossRef
    • Predictors of tuberculosis infection among adults visiting anti-retroviral treatment center at east and west Gojjam, northwest, Ethiopia, 2017
      Habtamu Belew, Moges Wubie, Getaye Tizazu, Abebaw Bitew, Tesfa Birlew
      BMC Infectious Diseases.2020;[Epub]     CrossRef
    • Bayesian Spatial Survival Analysis of Duration to Cure among New Smear-Positive Pulmonary Tuberculosis (PTB) Patients in Iran, during 2011–2018
      Eisa Nazar, Hossein Baghishani, Hassan Doosti, Vahid Ghavami, Ehsan Aryan, Mahshid Nasehi, Saeid Sharafi, Habibollah Esmaily, Jamshid Yazdani Charati
      International Journal of Environmental Research and Public Health.2020; 18(1): 54.     CrossRef
    • Correlation Between Clinical Manifestation and Radiological Findings In Pulmonary Tuberculosis-Human Immunodeficiency Virus Coinfection Patients In Sanglah Hospital, Bali, Indonesia
      Putu Satyakumara Upadhana, Haikal Hamas Putra Iqra, I Gusti Agung Ayu Chintya Cahyarini, I Ketut Agus Somia, Pande Putu Yuli Anandasari
      Current HIV Research.2020; 18(6): 426.     CrossRef
    • THE EFFECTIVENESS OF THE TREATMENT OF TUBERCULOSIS, COMBINED WITH HIV INFECTION IN THE TB FACILITY OF THE FEDERAL PENITENTIARY SERVICE, DEPENDING ON THE TYPE OF DRUG RESISTANCE OF THE PATHOGEN
      V. S. Borovitsky
      HIV Infection and Immunosuppressive Disorders.2019; 11(3): 64.     CrossRef
    • Multistate recursively imputed survival trees for time-to-event data analysis: an application to AIDS and mortality post-HIV infection data
      Leili Tapak, Michael R. Kosorok, Majid Sadeghifar, Omid Hamidi
      BMC Medical Research Methodology.2018;[Epub]     CrossRef
    • Identifying risk factors for progression to AIDS and mortality post-HIV infection using illness-death multistate model
      Omid Hamidi, Leili Tapak, Jalal Poorolajal, Payam Amini
      Clinical Epidemiology and Global Health.2017; 5(4): 163.     CrossRef
    • Treatment outcome of new smear positive pulmonary tuberculosis patients in Hamadan, Iran: A registry-based cross-sectional study
      Salman Khazaei, Jafar Hassanzadeh, Shahab Rezaeian, Ebrahim Ghaderi, Somayeh Khazaei, Abdollah Mohammadian Hafshejani, Hamid Salehiniya, Ali Zahiri
      Egyptian Journal of Chest Diseases and Tuberculosis.2016; 65(4): 825.     CrossRef
    • Survival rate of AIDS disease and mortality in HIV-infected patients: a meta-analysis
      J. Poorolajal, E. Hooshmand, H. Mahjub, N. Esmailnasab, E. Jenabi
      Public Health.2016; 139: 3.     CrossRef
    • Predictors of Tuberculosis in HIV/AIDS Patients Referred to Behavioral Diseases Consultation Center: A Registry-Based Study in Abadan, Southwest of Iran
      Salman Khazaei, Leila Molaeipoor, Shahab Rezaeian, Erfan Ayubi, Mehran Yari, Ali Asghar Valipour, Somayeh Khazaei
      Shiraz E-Medical Journal.2016;[Epub]     CrossRef
    • Prisoners co‐infected with tuberculosis and HIV: a systematic review
      Chantal L Edge, Emma J King, Kate Dolan, Martin McKee
      Journal of the International AIDS Society.2016;[Epub]     CrossRef
    • Predictors of human immunodeficiency virus and tuberculosis co-infection
      Venkataramana Kandi
      Epidemiology and Health.2015; 37: e2015007.     CrossRef

    Predictors of tuberculosis and human immunodeficiency virus co-infection: a case-control study
    Predictors of tuberculosis and human immunodeficiency virus co-infection: a case-control study
    Variables TB cases (HIV+/TB+)1 (n=241) Non-TB cases (HIV+/TB-)2 (n=2,147) Unadjusted OR (95% CI) p-value
    Gender
     Female 19 (7.88) 480 (22.36) 1.00
     Male 222 (92.12) 1,667 (77.64) 3.36 (2.08-5.43) 0.001
    Age (yr)
     18-29 47 (19.50) 636 (29.75) 1.00
     30-39 111 (46.06) 956 (44.71) 1.57 (1.10-2.24) 0.01
     ≥40 83 (34.44) 546 (25.54) 2.06 (1.41-3.00) 0.001
    Marital status
     Married 76 (32.76) 832 (40.88) 1.00
     Single 101 (43.53) 782 (38.43) 1.41 (1.03-1.93) 0.03
     Divorced 44 (18.97) 315 (15.48) 1.53 (1.03-2.27) 0.03
     Widowed 11 (4.74) 106 (5.21) 1.14 (0.58-2.21) 0.71
    Educational level
     High (>12 yr) 8 (3.72) 146 (7.97) 1.00
     Low (≤12 yr) 207 (96.28) 1,685 (92.03) 2.24 (1.08-4.63) 0.03
    Imprisonment
     No 48 (19.92) 839 (39.08) 1.00
     Yes 193 (80.08) 1,308 (60.92) 2.58 (1.86-3.58) 0.001
    Smoker
     No 65 (30.95) 853 (44.87) 1.00
     Yes 145 (69.05) 1,048 (55.13) 1.82 (1.34-2.47) 0.001
    Narcotic use
     No 80 (33.20) 1,042 (48.53) 1.00
     Yes 161 (66.80) 1,105 (51.47) 1.90 (1.43-2.51) 0.001
    Alcohol use
     No 221 (93.64) 2,031 (95.85) 1.00
     Yes 15 (6.36) 88 (4.15) 1.57 (0.89-2.76) 0.12
    Route of HIV transmission
     Sexual 21 (8.71) 494 (23.01) 1.00
     Intravenous drug users 116 (48.13) 751 (34.98) 3.63 (2.25-3.86) 0.001
     Transfusion 5 (2.07) 66 (3.07) 1.78 (0.65-4.89) 0.26
     Tattoos 2 (0.83) 26 (1.21) 1.81 (0.40-8.13) 0.44
     Surgery or dentistry 2 (0.83) 20 (0.93) 2.35 (0.52-10.73) 0.27
     Multiple exposure 87 (36.10) 680 (31.67) 3.01 (1.84-4.91) 0.001
     Unknown 8 (3.32) 110 (5.12) 1.71 (0.74-3.96) 0.21
    Sexual route of transmission
     Spouse 15 (16.85) 358 (34.52) 1.00
     Heterosexual 68 (76.40) 597 (57.57) 2.72 (1.53-4.83) 0.001
     Homosexual 1 (1.12) 26 (2.51) 0.92 (0.12-7.22) 0.93
     Bisexual 5 ( 5.62) 56 (5.40) 2.13 (0.75-6.09) 0.16
    Previous TB infection
     No 231 (95.85) 2,131 (99.25) 1.00
     Yes 10 (4.15) 16 (0.75) 5.77 (2.59-12.85) 0.001
    Hepatitis C virus
     No 111 (46.06) 1,253 (58.36) 1.00
     Yes 130 (53.94) 894 (41.64) 1.64 (1.26-2.15) 0.001
    Isoniazid preventive therapy
     No 234 (97.10) 1,811 (84.35) 1.00
     Yes 7 (2.90) 336 (15.65) 0.16 (0.08-0.35) 0.001
    Antiretroviral therapy
     No 1,356 (63.16) 136 (56.43) 1.00
     Yes 791 (36.84) 105 (43.57) 1.32 (1.01-1.73) 0.04
    CD4 cell count (cells/mm3)
     ≥350 33 (16.92) 656 (38.54) 1.00
     201-249 34 (17.44) 380 (22.33) 1.78 (2.66-6.62) 0.02
     50-200 74 (37.95) 410 (24.09) 3.59 (2.34-5.51) 0.001
     <50 54 (27.69) 256 (15.04) 4.19 (2.66-6.61) 0.001
     Trend test for strata of CD4 count 241 (100.00) 2,147 (100.00) 1.64 (1.43-1.88) 0.001
    Variables TB cases (HIV+/TB+)1 (n=241) Non-TB cases (HIV+/TB-)2 (n=2,147) Adjusted OR (95% CI) p-value
    Marital status
     Married 76 (32.76) 832 (40.88) 1.00
     Single 101 (43.53) 782 (38.43) 0.95 (0.63-1.45) 0.82
     Divorced 44 (18.97) 315 (15.48) 1.09 (0.66-1.81) 0.74
     Widow 11 (4.74) 106 (5.21) 1.57 (0.72-3.39) 0.25
    Educational level
     High (>12 yr) 8 (3.72) 146 (7.97) 1.00
     Low (≤12 yr) 207 (96.28) 1,685 (92.03) 0.93 (0.43-2.05) 0.86
    Imprisonment
     No 48 (19.92) 839 (39.08) 1.00
     Yes 193 (80.08) 1,308 (60.92) 3.82 (2.11-6.90) 0.001
    Smoker
     No 65 (30.95) 853 (44.87) 1.00
     Yes 145 (69.05) 1,048 (55.13) 1.27 (0.77- 2.10) 0.36
    Previous TB infection
     No 231 (95.85) 2,131 (99.25) 1.00
     Yes 10 (4.15) 16 (0.75) 5.54 (1.99- 15.39) 0.001
    Isoniazid preventive therapy
     No 234 (97.10) 1,811 (84.35) 1.00
     Yes 7 (2.90) 336 (15.65) 0.13 (0.06-0.31) 0.001
    Antiretroviral therapy
     No 1,356 (63.16) 136 (56.43) 1.00
     Yes 791 (36.84) 105 (43.57) 1.81 (1.26-2.61) 0.001
    CD4 cell count (cells/mm3)
     ≥350 33 (16.92) 656 (38.54) 1.00
     201-249 34 (17.44) 380 (22.33) 2.15 (1.25-3.72) 0.006
     50-200 74 (37.95) 410 (24.09) 3.31 (2.01-5.45) 0.001
     <50 54 (27.69) 256 (15.04) 4.57 (2.69-7.76) 0.001
     Trend test for strata of CD4 count 241 (100.00) 2,147 (100.00) 1.70 (1.45-1.99) 0.001
    Table 1. Results from the bivariate logistic regression analysis of binary and continuous predictors of M. tuberculosis/HIV co-infection using unadjusted odds ratios (ORs)

    HIV, human immunodeficiency virus;TB, tuberculosis; CI, confidence interval.

    HIV+/TB+, human immunodeficiency virus positive patients with Mycobacterium tuberculosis co-infection;

    HIV+/TB-, human immunodeficiency virus positive patients without Mycobacterium tuberculosis co-infection.

    Table 2. Results from the multivariate logistic regression analysis of binary and continuous predictors of M. tuberculosis/HIV co-infection using odds ratios (ORs) adjusted for all other variables in the model (pseudo R2=0.144)

    HIV, human immunodeficiency virus; TB, tuberculosis; CI, confidence interval.

    HIV+/TB+, human immunodeficiency virus positive patients with Mycobacterium tuberculosis co-infection;

    HIV+/TB-, human immunodeficiency virus positive patients without Mycobacterium tuberculosis co-infection.

    Table 1.

    Table 2.

    Epidemiol Health : Epidemiology and Health
    © Korean Society of Epidemiology.
    TOP